Cipla Past Earnings Performance

Past criteria checks 5/6

Cipla has been growing earnings at an average annual rate of 17.7%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 9.2% per year. Cipla's return on equity is 14.9%, and it has net margins of 14.8%.

Key information

17.7%

Earnings growth rate

17.7%

EPS growth rate

Pharmaceuticals Industry Growth	17.5%
Revenue growth rate	9.2%
Return on equity	14.9%
Net Margin	14.8%
Next Earnings Update	10 May 2024

Recent past performance updates

Recent updates

Cipla Limited (NSE:CIPLA) Shares Could Be 34% Above Their Intrinsic Value Estimate

Apr 30

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Mar 23

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Dec 18

Calculating The Fair Value Of Cipla Limited (NSE:CIPLA)

Dec 05

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Oct 27

If You Like EPS Growth Then Check Out Cipla (NSE:CIPLA) Before It's Too Late

Sep 16

Cipla Limited (NSE:CIPLA) Shares Could Be 23% Above Their Intrinsic Value Estimate

Aug 31

It's Unlikely That Cipla Limited's (NSE:CIPLA) CEO Will See A Huge Pay Rise This Year

Aug 18

Cipla (NSE:CIPLA) Could Easily Take On More Debt

Jul 12

Are Cipla Limited (NSE:CIPLA) Investors Paying Above The Intrinsic Value?

May 28

Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?

Mar 21

Here's Why I Think Cipla (NSE:CIPLA) Is An Interesting Stock

Mar 08

Revenue & Expenses Breakdown
Beta

How Cipla makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:CIPLA Revenue, expenses and earnings (INR Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	251,163	37,082	53,757	0
30 Sep 23	243,407	34,532	52,563	0
30 Jun 23	235,108	31,112	51,260	0
31 Mar 23	225,593	28,019	50,151	0
31 Dec 22	222,187	26,383	48,947	0
30 Sep 22	218,874	25,660	48,184	0
30 Jun 22	216,105	24,884	35,984	0
31 Mar 22	217,078	25,168	46,669	0
31 Dec 21	210,718	25,681	43,285	0
30 Sep 21	207,616	25,876	43,004	0
30 Jun 21	202,801	25,417	42,435	0
31 Mar 21	191,205	24,049	41,281	0
31 Dec 20	188,779	22,374	40,432	0
30 Sep 20	180,802	18,403	39,444	0
30 Jun 20	174,377	16,462	38,851	0
31 Mar 20	170,805	15,465	38,694	0
31 Dec 19	171,206	16,678	38,608	0
30 Sep 19	167,572	16,489	38,331	0
30 Jun 19	163,733	15,546	37,837	0
31 Mar 19	163,232	15,277	37,415	0
31 Dec 18	155,224	13,391	35,683	0
30 Sep 18	154,287	14,074	35,078	0
30 Jun 18	154,992	14,530	34,564	0
31 Mar 18	151,053	14,105	34,151	0
31 Dec 17	147,618	11,701	32,973	0
30 Sep 17	144,951	11,444	32,730	0
30 Jun 17	141,637	10,762	32,875	0
31 Mar 17	143,340	10,064	33,011	0
31 Dec 16	142,509	11,213	31,554	0
30 Sep 16	137,547	10,071	31,012	0
30 Jun 16	134,335	12,219	30,089	0
31 Mar 16	135,480	13,600	29,258	0
31 Dec 15	135,044	16,847	39,028	1,120
30 Sep 15	131,633	16,694	38,220	1,120
30 Jun 15	124,782	15,368	37,096	1,120
31 Mar 15	113,454	11,808	23,549	0
31 Dec 14	106,195	11,818	32,156	1,058
30 Sep 14	105,627	11,383	31,333	1,058
30 Jun 14	104,164	11,976	30,224	1,058
31 Mar 14	101,734	13,884	29,546	1,058
31 Dec 13	94,330	14,042	25,122	432
30 Sep 13	89,509	14,602	23,641	432
30 Jun 13	86,548	15,901	22,631	432

Quality Earnings: CIPLA has high quality earnings.

Growing Profit Margin: CIPLA's current net profit margins (14.8%) are higher than last year (11.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CIPLA's earnings have grown by 17.7% per year over the past 5 years.

Accelerating Growth: CIPLA's earnings growth over the past year (40.5%) exceeds its 5-year average (17.7% per year).

Earnings vs Industry: CIPLA earnings growth over the past year (40.5%) exceeded the Pharmaceuticals industry 23.3%.

Cipla Past Earnings Performance

Past criteria checks 5/6

Key information

Recent past performance updates

Cipla Limited to Report Q4, 2024 Results on May 10, 2024

Third quarter 2024 earnings: EPS exceeds analyst expectations

Second quarter 2024 earnings released: EPS: ₹14.01 (vs ₹9.78 in 2Q 2023)

Cipla Limited to Report Q2, 2024 Results on Oct 27, 2023

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited to Report Q1, 2024 Results on Jul 26, 2023

Recent updates

With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case

Cipla Limited to Report Q4, 2024 Results on May 10, 2024

Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024

Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Price target increased by 8.7% to ₹1,391

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson

Third quarter 2024 earnings: EPS exceeds analyst expectations

Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Second quarter 2024 earnings released: EPS: ₹14.01 (vs ₹9.78 in 2Q 2023)

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Cipla Limited to Report Q2, 2024 Results on Oct 27, 2023

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Blackstone Reportedly Withdraws Plan to Acquire Founders' Stake in Cipla

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Cipla's Founding Family's Stake Sale Reportedly in Jeopardy over $13 Billion Valuation Target

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Blackstone Reportedly to Submit Bid for over 33% Stake in Cipla

Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?

Cipla Promoters Reportedly Mull Stake Sale to Top PE Firms Blackstone, Baring Asia

Cipla Limited Announces Change in Management

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited, Annual General Meeting, Aug 10, 2023

Cipla Limited to Report Q1, 2024 Results on Jul 26, 2023

Shibam Group Holding Limited entered into a binding term sheet to acquire additional 51% stake in Saba Investment Ltd from Cipla Limited (NSEI:CIPLA) for $6.5 million.

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited Announces Resignation of Peter Mugyenyi as Independent Director, Effective May 13, 2023

Is Cipla (NSE:CIPLA) A Risky Investment?

A Look At The Fair Value Of Cipla Limited (NSE:CIPLA)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Cipla Limited Announces the Launch of Cippoint

Cipla Limited to Report Q3, 2023 Results on Jan 25, 2023

Cipla (NSE:CIPLA) Has A Pretty Healthy Balance Sheet

Cipla Limited and Cipla Usa Inc. Announces the Launch of Leuprolide Acetate Injection Depot 22.5Mg

Price target increased to ₹1,208

Price target increased to ₹1,202

Second quarter 2023 earnings: EPS exceeds analyst expectations

Cipla Limited to Report Q2, 2023 Results on Nov 04, 2022

Cipla Limited Receives the Establishment Inspection Report Indicating Closure of the Inspection

Cipla Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Cipla Limited (NSEI:CIPLA) agreed to acquire additional 13.10% stake in Jiangsu Acebright Pharmaceutical Co. Limited for USD 16.40 million.

Estimating The Fair Value Of Cipla Limited (NSE:CIPLA)

Cipla Limited Announces Executive Changes

Upcoming dividend of ₹5.00 per share

First quarter 2023 earnings released: EPS: ₹8.51 (vs ₹8.86 in 1Q 2022)

Cipla Limited, Annual General Meeting, Aug 26, 2022

Cipla (NSE:CIPLA) Will Pay A Dividend Of ₹5.00

Cipla Limited Recommends Final Dividend for Fiscal Year 2021-22

Cipla (NSE:CIPLA) Could Easily Take On More Debt

Cipla Limited to Report Q1, 2023 Results on Jul 29, 2022

Cipla Limited Notifies That the United States Food and Drug Administration Conducted A Pre Approval Inspection

If EPS Growth Is Important To You, Cipla (NSE:CIPLA) Presents An Opportunity

Cipla Limited (NSEI:CIPLA) agreed to acquire unknown stake in GoApptiv Private Limited.

Cipla Limited (NSEI:CIPLA) entered into a definitive agreement to acquire an unknown minority stake in Achira Labs Pvt. Ltd

The South African Health Products Regulatory Authority Approves Sweet-Tasting, Heat-Stable, 4-In-1 Fixed-Dose Combination of Four Antiretroviral Treatments Developed by Cipla and DNDi

Cipla Limited Recommends Dividend for the Year 2021-22

Third quarter 2022 earnings: EPS misses analyst expectations

Consensus forecasts updated

Cipla Limited Announces Commercialisation of `RT-Direct' multiplex COVID-19 RT PCR Test kit in India

Cipla Limited (NSE:CIPLA) Shares Could Be 34% Above Their Intrinsic Value Estimate

Cipla Limited to Report Q4, 2022 Results on May 10, 2022

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Revenue & Expenses Breakdown
Beta